Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RZL-012 for Submental Fat Reduction in Chinese vs. Non-Chinese Subjects
NCT05466448Phase 2Completed
- Sponsor
- Raziel Therapeutics
- Start
- Jul 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Tapencarium in submental fat, sponsored by Raziel Therapeutics. Started Jul 2022; status: completed.
02
Drugs
Tapencarium
03
Conditions
submental fat
Beyond the preview
Go deeper on NCT05466448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05466448.